Corporate ActionJul 31, 2026, 04:19 PM
NeuroSense Updates ATM Facility, Can Sell Up To $3.79M Shares
AI Summary
NeuroSense Therapeutics Ltd. amended its Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC. This update references a newly effective registration statement, enabling the company to offer and sell ordinary shares with an aggregate offering price of up to $3,789,822. As of July 31, 2026, NeuroSense had already sold 6,762,825 ordinary shares under the original agreement, generating approximately $6.7 million in net proceeds.
Key Highlights
- NeuroSense Therapeutics Ltd. amended its Capital on Demand™ Sales Agreement.
- The amendment updates references to a new registration statement on Form F-3.
- Company can now offer and sell ordinary shares up to $3,789,822 under the agreement.
- Previously sold 6,762,825 ordinary shares for net proceeds of approximately $6.7 million.
- The original Sales Agreement remains in full force and effect, as amended.
Price Impact
More from NRSN